# OnCo record nct05816252 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05816252/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05816252", "NCT05816252" ;
  schema:name "A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-"@en ;
  schema:description "A phase 2 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Klus Pharma Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05816252/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05816252> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-04-19" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/> .